Set, Setting, and the One Variable Nobody Measures

Ask anyone in this field what determines a psychedelic experience and you'll hear the same two words. Set and setting. Your mindset going in, and the environment you're in. It's a genuinely good insight, and it's why preparation and integration exist as disciplines at all. ‍

But there's a third thing, and it sits underneath both of the others. Your internal biochemistry on the day. For roughly half the population, that biochemistry is not a fixed baseline. It moves on a monthly cycle, shifts across the reproductive lifespan, and changes again with contraceptives or hormone therapy.

A narrative review published in Molecular Psychiatry in August 2026 by Kim Kuypers and colleagues at Maastricht University pulls together what's known. The short answer is that the mechanisms are plausible and mostly unmeasured. That gap is worth understanding, because it shapes what we can and can't say about psychedelics and women's mental health right now.

What we do know

Start with the part that isn't in dispute.

Women carry a disproportionate share of depression, anxiety, PTSD, and eating disorders. And for many women, the severity of those symptoms is not stable across the month. Systematic reviews have documented perimenstrual worsening in anxiety disorders, PTSD, and OCD. Bipolar symptoms often intensify premenstrually. Psychotic symptoms show a perimenstrual increase that appears to track the drop in estradiol. Binge eating rises in the mid-to-late luteal phase. Premenstrual dysphoric disorder is the clearest case of all, with symptoms arriving reliably as progesterone and estradiol fall.

This isn't controversial. It's decades of clinical observation with the research to back it.

Second piece: sex hormones change how the body handles drugs. Progesterone slows gastrointestinal transit, which affects how quickly something taken by mouth gets absorbed. Estradiol and progesterone both influence liver enzymes, including CYP3A4 and CYP2D6, which happen to be central to how the body processes LSD and psilocin. Body composition and fluid balance shift across the cycle, changing how a compound distributes through tissue.

None of this is speculative pharmacology. It's the same reason antidepressant response and side effect profiles can vary by cycle phase.

Third piece, and this is the one that should get attention. Classic psychedelics work primarily through the serotonin 2A receptor. Estradiol appears to regulate that receptor. PET imaging studies in postmenopausal women found that estrogen therapy increased cortical 5-HT2A binding, including in prefrontal regions. Women who have gone through menopause without hormone therapy show lower receptor availability than cycling women.

Put plainly: the receptor these substances act on is not a fixed quantity. It varies with hormonal state.

What we don't know

Here's where it gets thin.

No human study has directly measured how menstrual cycle phase affects psychedelic pharmacokinetics. Not one. The review says so explicitly: direct human data for psychedelics remain absent. Almost everything connecting hormonal state to psychedelic response is inference, drawn from general pharmacological principles and from receptor studies conducted for other reasons.

It's also worth knowing what kind of paper this is. A narrative review synthesizes existing literature and builds an argument. It isn't a systematic review with pooled data, and it isn't new evidence. The authors are admirably clear about this and flag the limitation repeatedly. Some of the receptor work comes from platelet binding assays, and whether platelet findings translate to the brain is an open question. Where clinical evidence was missing entirely, they had to reach for preclinical work.

The review does suggest that subjective and adverse effects might be most pronounced during the early-to-mid follicular and early luteal phases. That is a hypothesis. It is not a finding, and it is emphatically not a dosing schedule.

Why the gap exists

This is the part I find hardest to sit with.

A scoping review published in 2025 looked at psychedelic research for substance use disorders and found female participation in clinical trials running at 19%, which is 372 participants out of 1,922. Seventy percent of the studies didn't do anything with sex beyond reporting how many women were enrolled. None treated sex or gender as a central analytic focus. Historically it's worse: 13.3% female participation before 1990, improving only to 27% after.

The reasoning behind excluding women from trials was always circular. Hormonal fluctuation makes results messier, so exclude the people who fluctuate, so the results stay clean, so we never learn what the fluctuation does.

And there's a detail I can't stop thinking about. Researchers have pointed out that when a trial protocol schedules dosing sessions four weeks apart, each participant ends up being dosed at roughly the same point in her cycle every single time. Whatever effect cycle phase has, it gets baked into her results consistently and invisibly. A structural blind spot hiding inside a scheduling convention.

This is the same class of problem that surfaced in the FDA's rejection of MDMA-assisted therapy. Design choices made for convenience or cleanliness turn out to determine what the trial can and cannot detect.

The postpartum caution

One finding deserves separate mention because it runs against the optimistic grain, and because it's stronger than a passing reference would suggest.

There's real interest in psychedelics for postpartum depression, and the reasoning is sound on paper. A 2025 study in Nature Communications from David Olson and Danielle Stolzenberg's groups at UC Davis tested it in a mouse model of peripartum mood disorder. Psilocybin did not ameliorate any of the stress-related maternal behaviors. Weeks after a single dose, the treated mothers were more anxious than untreated ones, and this held regardless of whether they'd been stressed at all. The researchers described them as dramatically impaired and said they were shocked by it.

The comparison group is what makes this hard to dismiss. Virgin female mice given the same single dose showed the expected anxiolytic effect. Reproductive status was the variable that flipped the direction of the result.

Offspring exposed to psilocin through breastmilk showed anhedonia in adulthood.

That's animal work, with all the translation caveats, and it should be held as animal work. But it's the opposite of what the enthusiasm predicted. And Phase 2 trials are currently recruiting postpartum parents for a psilocybin analogue, which makes this a live question rather than a theoretical one.

What this actually means

I want to be careful here, because there's an obvious wrong conclusion available.

The wrong conclusion is that women should now be timing sessions to their cycle. The evidence does not support that. Nobody has measured it. Anyone offering cycle-timing protocols right now is extrapolating well past what exists.

The right conclusion is more modest and, I think, more useful. If you're a woman who has had psychedelic experiences that varied a lot in intensity for reasons you couldn't explain, there may be a real biological contributor, and the inconsistency was not a failure of your preparation. And if you're working with a practitioner, hormonal context belongs in the intake conversation the same way sleep and medication do.

A few things worth knowing about yourself or asking a client about:

Cycle phase, if applicable, and whether symptoms follow a predictable monthly pattern. Contraceptive use, since synthetic hormones appear to reshape receptor dynamics rather than simply stabilizing them. Menopausal status and whether hormone therapy is in the picture, along with the formulation and route, because transdermal and oral estradiol behave differently. And SSRI status, which matters most of all, since SSRIs are first-line for PMDD and there's actual human data showing they can blunt the acute effects of psilocybin.

That last one is the only item on the list with solid human evidence behind it. Everything else is a question to hold, not a variable to optimize.

A note on scope

This research concerns classic serotonergic psychedelics taken orally: psilocybin, LSD, ayahuasca. Ketamine acts through a different receptor system, so the 5-HT2A mechanism at the center of this work doesn't transfer to ketamine-assisted therapy. The general pharmacokinetic points aren't receptor-specific and could in principle apply, but nobody has studied that either. The broader point about women being understudied still stands.

Sitting with not knowing

The honest position is that we're at the beginning. We know women's neurochemistry moves in ways that should plausibly change how these substances work. We know the research hasn't looked. We don't know what we'd find if it did.

That's starting to change, at least. A trial protocol published in August 2026 sets out to test menstrual cycle effects and tolerability of low-dose psilocybin in healthy menstruating people, which is close to the study this whole literature has been missing. One protocol isn't a body of evidence. But it means the question is finally being asked directly rather than inferred around.

Until then, the unsatisfying place to land is where the evidence actually is. There's a version of this field that fills uncertainty with confident protocols, and a version that names the gap and keeps working. The second one is slower. It's also the one that ends up knowing something.